The Cold Ischemia Robot-assisted Partial Nephrectomy
The Impact of Cold Ischemia on Recovery From Ischemia After Robot-assisted Partial Nephrectomy: A Randomized Controlled Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Fangjian Zhou, professor
- Phone Number: 020-87343865
- Email: zhoufj@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- 651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Sun Yat-sen University Cancer Center;
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 80 years old; 2. Intending to perform robot-assisted partial nephrectomy
Exclusion Criteria:
- Anesthesiologist assessment: Patient unsuitable for general anesthesia;
- Having severe cardiovascular and cerebrovascular diseases;
- horseshoe kidney;
- pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cold ischemia
During the surgical procedure, employing ice to achieve local hypothermia in the kidneys.
|
During the surgical procedure, employing ice to achieve local hypothermia in the kidneys.
|
|
Active Comparator: Warm ischemia
Not applying local hypothermia to the kidneys during the surgical procedure
|
Not applying local hypothermia to the kidneys during the surgical procedure
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery from ischemia
Time Frame: 1-12 months after surgery
|
(%GFR saved)/(%parenchymal mass preserved)
|
1-12 months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
surgical duration
Time Frame: Intraoperative
|
The duration of the surgery
|
Intraoperative
|
|
surgical complications
Time Frame: 1-12 months after surgery
|
Intraoperative and postoperative complication incidence rate
|
1-12 months after surgery
|
|
The extent of decline in the long-term GFR (month13-24) on the operated kidney compared to the new baseline GFR(months 1-12).
Time Frame: up to 2 years after surgery
|
Postoperative short-term GFR(months 1-12) minus long-term GFR(month13-24)
|
up to 2 years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Fangjian Zhou, professor, Sun Yat-sen University Cancer Center (SYSUCC)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
Other Study ID Numbers
Other Study ID Numbers
- SL-B2022-518-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
NCT05122546Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell Carcinoma | Advanced Papillary Renal Cell Carcinoma | Advanced Sarcomatoid Renal Cell Carcinoma
-
NCT07227415RecruitingCarcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Metastatic Renal Cell Cancer | Renal Cancer | Advanced Renal Cell Carcinoma | Renal Neoplasm | Advanced or Metastatic Renal Cell Carcinoma | Clear-cell Metastatic Renal Cell Carcinoma | Carcinoma, Renal Cell, Advanced
-
NCT07218692Not yet recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal Cell Carcinoma
-
NCT07179770RecruitingMetastatic Clear Cell Renal Cell Carcinoma
-
NCT06399419RecruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal Cell Carcinoma
-
NCT07615348Not yet recruitingMetastatic Clear Cell Renal Cell Carcinoma
-
NCT00126503CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma
-
NCT04413123Active, not recruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell Carcinoma
-
NCT07128680RecruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Sarcomatoid Renal Cell Carcinoma
-
NCT06866262RecruitingMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Locally Advanced Clear Cell Renal Cell Carcinoma | Locally Advanced Sarcomatoid Renal Cell Carcinoma
Clinical Trials on Cold ischemia robot-assisted partial nephrectomy
-
NCT02924597Unknown
-
NCT03679572Unknown
-
NCT06715878Recruiting
-
NCT07065825Not yet recruitingKidney Cancer | Renal Neoplasms
-
NCT06441851Not yet recruiting
-
NCT03624673Active, not recruiting
-
NCT06572501RecruitingRenal Tumor | Prone Position | Robotic Assisted Partial Nephrectomy
-
NCT02734329Unknown
-
NCT05572216Recruiting
-
NCT05089006Completed